


## Designed to be different: A powerful, non-antibiotic dose

### ORACEA® 40 MG\* CAPSULES PROVIDE SUSTAINED ANTI-INFLAMMATORY EFFECT WITH LOW PLASMA VARIABILITY<sup>1,2</sup>



**The burden of rosacea is more than skin deep. Precisely designed oral treatments can provide fast-acting and long-lasting therapy for your patients that may also improve their confidence and overall quality of life.<sup>3,4</sup>**

However, as the rise of antibiotic resistance continues to gain more interest across the healthcare industry, the array of health implications it presents – for both current patients and the generations to come – are only just coming to light. Antibiotic resistance is one of the biggest health challenges of our time and represents a global threat.<sup>5</sup>

Given that rosacea is a chronic condition and often requires treatment for extended periods of time, it is crucial to prescribe an option that keeps your patients below the antimicrobial threshold.<sup>1</sup>

With ORACEA® (doxycycline, USP) Capsules 40 mg, Galderma remains committed to the global fight against antibiotic resistance. Unlike higher-dose doxycyclines, such as 50 or 100 mg, ORACEA Capsules is formulated to effectively treat inflammatory lesions of rosacea without crossing the antimicrobial threshold.<sup>1,2</sup> ORACEA Capsules contain a gradual-release mechanism\* over 24 hours, providing sustained anti-inflammatory effects with low plasma variability.<sup>1,2,6-8</sup> ORACEA Capsules consist of a combination of immediate-release (30 mg) and delayed-release (10 mg) beads. Designed specifically to treat the inflammatory lesions of rosacea, ORACEA Capsules provide powerful anti-inflammatory effects, without the antimicrobial activity due to its non-antibacterial dose.<sup>1,2,9-11</sup> Supported by evidence from a long-term study<sup>†</sup>, the non-antibiotic dose has been shown to be highly efficacious, all while evading treatment-emergent antimicrobial resistance. Additionally, no alterations in normal bacterial microflora were observed.<sup>2,11</sup>

By prescribing ORACEA Capsules, not only are you keeping your patients below the antimicrobial threshold, you're offering them visible results that may be seen in four weeks, with less than half the dosage of doxycycline.<sup>10</sup>

Rosacea is a chronic disease.

The goal of treatment is to control its symptoms and rate of relapse in the safest and most effective way possible, improving the quality of life for all those who suffer from rosacea.<sup>1</sup> Choose ORACEA Capsules: A powerful once-daily dose; specifically designed for the inflammatory lesions of rosacea, without crossing the antimicrobial threshold.<sup>1,2,6-14</sup>

#### Important Safety Information ORACEA® (doxycycline, USP) 40 mg Capsules

**Indication:** ORACEA® (doxycycline, USP) 40 mg\* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. **Adverse Events:** In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. **Warnings/Precautions:** ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/safety/medwatch](http://www.fda.gov/safety/medwatch) or call 1-800-FDA-1088.

\*30 mg immediate release and 10 mg delayed release beads

#### REFERENCES

1. Fowler JF. Anti-inflammatory dose doxycycline for the treatment of rosacea. *Expert Rev Dermatol*. 2007;2(5):523-531. 2. Baldwin HE. Diagnosis and treatment of rosacea: state of the art. *J Drugs Dermatol*. 2012;11(6):725-730. 3. Rosacea: Beyond the visible report. Available at: <https://hosted.bmj.com/rosaceabeyondthevisible>. Accessed: October 2020. 4. Huynh T. Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life. *Am Health Drug Benefits* 2013;6:348-354. 5. Centers for Disease Control and Prevention 2020. Combat antimicrobial resistance globally. Available at: <https://www.cdc.gov/drugresistance/intl-activities.html>. Accessed: October 2020. 6. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2013. 7. Etchegaray JP, Wagner N, Shah MS, Difalco RJ, inventors; Galderma S.A., Cerovene, Inc. assignees. Doxycycline formulations, and methods of treating rosacea. US Patent 8,652,516 B1. February 18, 2014. 8. Data on file. ORACEA PK Profile. Galderma Laboratories, L.P. 9. Del Rosso JQ, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. *J Am Acad Dermatol*. 2007;56(5):791-802. 10. Del Rosso JQ, et al. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. *J Drugs Dermatol*. 2008;7(8):573-576. 11. Preshaw PM, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planning in subjects with periodontal disease. *J Periodontol*. 2008;79(3):440-452. 12. Bhatia N. ORACEA 40 mg capsules for papulopustular rosacea. *The Dermatologist*. 2013;6(21s):1-4. Available at: <https://pdfs.semanticscholar.org/363e/66311811307ccfd9e9d8bd8b594bdaf4254.pdf>. Accessed: October 2020. 13. Theobald K, et al. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. *Skinmed*. 2007;6(5):221-226. 14. Wise RD. Sub microbial doxycycline and rosacea. *Compr Ther*. 2007;33(2):78-81.

\*30 mg immediate release and 10 mg delayed release beads

†As found in a 9-month clinical study<sup>11</sup>

‡Sixteen healthy subjects in the ORACEA Capsules are measured at 7 days; mean weight 75 kg

US-ORC-2000001  
12/2020

© 2020 Galderma Laboratories, L.P. United States, All Rights Reserved.  
All trademarks are the property of their respective owners.